Wednesday, August 23, 2023
MGI and NGeneBio have recently entered into a memorandum of understanding (MOU) with the aim of expanding the global availability of NGeneBio's cancer testing products.
This collaboration involves leveraging NGeneBio's advanced NGS (Next-Generation Sequencing) cancer precision diagnosis products on MGI's sequencing platform, specifically the DNBSEQ-G99. This partnership will grant healthcare professionals access to a robust and dependable tool for precision diagnosis and personalised treatment.
NGeneBio and MGI are collaborating to develop an integrated precision diagnostic platform with the goal of improving the accuracy and efficiency of diagnostic tests. This partnership also involves regional clinical trials and collaborations in the Asia-Pacific (APAC) region, aimed at expanding the accessibility and utilisation of advanced NGS solutions.
This strategic partnership brings together NGeneBio's advanced diagnostic assays and MGI's high-throughput sequencing technology. The goal is to accelerate the development and application of innovative sequencing products within the realm of precision medicine. This advancement aims to provide patients with greater access to accurate diagnostics and personalised treatment options.
